<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511066</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P27 2.2</org_study_id>
    <nct_id>NCT03511066</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy, Safety of CT-P27 in Acute Uncomplicated Influenza A Infection</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects With Acute Uncomplicated Influenza A Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the Efficacy and Safety of CT-P27 comparing placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the Efficacy and Safety of CT-P27 comparing placebo in Subjects
      with Acute Uncomplicated Influenza A Infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy;Symptom</measure>
    <time_frame>Daily to Biweekly up to 16 weeks</time_frame>
    <description>Resolution of Respiratory symptom, Constitutional Symptom</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>CT-P27 Dose1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P27 will be administrated once in IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P27 Dose2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P27 will be administrated once in IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administrated once in IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-P27 Dose1</intervention_name>
    <description>Influenza A treatment drug.</description>
    <arm_group_label>CT-P27 Dose1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-P27 Dose2</intervention_name>
    <description>Influenza A treatment drug.</description>
    <arm_group_label>CT-P27 Dose2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female subjects between the ages of 19 and 65 years, both inclusive

          -  Diagnosed with influenza A at screening.

          -  â‰¥38'C body temperature at screening

        Exclusion Criteria:

          -  Taking antiviral treatment for influenza or has a history of using these antivirals
             within 14 days prior to the administration of study drug.

          -  Positive influenza B or A+B infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SuEun Song</last_name>
    <role>Study Director</role>
    <affiliation>Celltrion Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ByeongHyeon Kim</last_name>
    <phone>82 32 850 6566</phone>
    <email>ByeongHyeon.Kim@celltrion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WooJoo Kim, MD</last_name>
      <phone>822-2626-3051</phone>
      <email>wjkim@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

